In order to prevent spam,
this email address cannot be copied.
Schizophrenia Research Forum: Researcher Profile - Robert McClure
Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
Research News
Conference News
Plain English
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
What We Know
Animal Models
Drugs in Trials
Research Tools
Community Calendar
General Information
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
Researcher Profile - Robert McClure

First Name:Robert
Last Name:McClure
Advanced Degrees:M.D.
Affiliation:University of North Carolina at Chapel Hill
Department:Department of Psychiatry
Street Address 1:School of Medicine, Department of Psychiatry
Street Address 2:Campus Box #7160, Room #247, Wing C
City:Chapel Hill
Zip/Postal Code:27599-7160
Email Address:
(view policy) 
Member reports the following financial or other potential conflicts of interest: [Last Modified: 24 February 2011]

POTENTIAL financial conflicts of interest:

(1.)2002-2005: received speaker or consulting fees and/or travel reimbursement:
(a.) for giving a few non-promotional presentations on the topic of recovery in schizophrenia, sponsored by Jannsen;
(b.) for giving a non-promotional presentation on the topic of antipsychotics michanism of action, sponsored by Pfizer, and;
(c.) for serving as a consultant on occasion for Abbott.

(2.) 2008: received travel and/or lodging reimbursement, and/or waived conference fees for attendance at a clinical educational conference in Minneapolis, Minnesota. The sponsor was Medtronics, the only medical device manufacturer with a human device exemption from the FDA for for deep brain stimulation in treatment-resistant obsessive compulsive disorder.

(3.) 2011: received travel and/or lodging reimbursement, and/or waived conference fees for attendance at clinical educational conference in Atlanta, GA. The sponsor was Neuronetics, a medical device manufacturer of a proprietary rTMS system with an FDA indication for treatment of adults with a major depressive disorder who have not responded to one adequate treatment trial of an antidepressant.

(4.) UNC School of Medicine's policy requires report of any income earned from a single commercial source, that exceeds 10% of a faculty member's current university salary. At no time has any reimbursement from any commercial interest even approached this reportable level.
View all comments by Robert McClure
Clinical Interests:
Schizophrenia, Anxiety disorders , Neurodevelopmental disorders (e.g., 22q11 deletion syndromes), Attention-deficit hyperactivity disorder (ADHD, ADD) , Bipolar disorder , Depression
Research Focus:
Brain stimulation therapies (ECT, VNS, rTMS, DBS), Brain imaging
Work Sector(s):
Web Sites:
Reasearcher Bio
to follow
Top Papers
to follow
What are the top three papers (not yours) you have read recently?
to follow
If resources were not limited, what research projects would you pursue?
to follow
What is your leading hypothesis?
to follow
What piece of missing evidence would help prove it?
to follow
What is your fallback position?
to follow

Research Participants
Copyright © 2005- 2016 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright